(This document is a summary English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.)

February 27, 2025

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Masashi Sugimoto, President and COO
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL:06-6758-8223)

Notice Regarding Result and Completion of Repurchase of Shares through an Off-Auction Own Share Repurchase Transaction (ToSTNeT-3) (Repurchase of Shares pursuant to Provisions of Articles of Incorporation in accordance with Article 459, Paragraph 1 of the Companies Act)

ROHTO PHARMACEUTICAL CO., LTD. (the "Company") hereby announces that it conducted a repurchase of its own shares today as follows, as announced on February 26, 2025.

The Company also hereby announces that, with this repurchase, the completion of the repurchase of its own shares pursuant to the resolution of the Board of Directors as of February 26, 2025.

1. Reason for Repurchase of Shares

The Company intends to repurchase its own shares in order to improve return on equity and earnings per share, as well as for smoothly carrying out fundraising by mitigating the short-term impact on demand and supply for the Company's Shares accompanied by the issuance of the Zero Coupon Convertible Bonds due 2032.

2. Matters regarding Repurchase

(1)	Class of Shares Repurchased	Common stock
(2)	Total Number of Shares Repurchased	2,174,300 shares
(3)	Total Repurchase Price	¥4,999,802,850
(4)	Repurchase Date	February 27, 2025
(5)	Repurchase Method	Repurchase through an off-auction own share repurchase transaction in the Tokyo Stock Exchange (ToSTNeT-3)

Note: This press release is intended as general information regarding the result of ROHTO Pharmaceutical Co., Ltd.'s repurchase of its own shares. This press release does not constitute an offer to purchase or subscribe for, or the solicitation of an offer to purchase or subscribe for the Company's convertible bonds with stock acquisition rights (the "Bonds") or the shares of common stock of the Company in the United States or in any jurisdiction in which such offer or solicitation is unlawful. In particular, the Bonds and the shares of common stock of the Company issuable upon exercise of the stock acquisition rights (together, the "Securities") have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state or other jurisdictions of the United States, and any such Securities may not be offered or sold within the United States, absent registration or an exemption from registration under the Securities Act, and in compliance with any applicable state or local securities laws; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company. No public offering of the Securities will be made in the United States.

(Reference)

1. Resolution of the Board of Directors as of February 26, 2025 regarding Repurchase of Shares

- Class of Shares to be Repurchased	Common stock
- Total Number of Shares which may be Repurchased	Up to 2,430,000 shares (approximately 1.07% of the total issued shares as of December 31, 2024 (excluding treasury stock))
- Total Repurchase Price of Shares	Up to ¥5 billion
- Repurchase Period	From February 27, 2025 to April 30, 2025
- Repurchase Method	Market purchase (including an off-auction purchase transaction) at the Tokyo Stock Exchange

2. Progress of Repurchase of Shares as of February 27, 2025

- Total Number of Shares Repurchased	2,174,300 shares
- Total Repurchase Price of Shares	¥4,999,802,850

Note: This press release is intended as general information regarding the result of ROHTO Pharmaceutical Co., Ltd.'s repurchase of its own shares. This press release does not constitute an offer to purchase or subscribe for, or the solicitation of an offer to purchase or subscribe for the Company's convertible bonds with stock acquisition rights (the "Bonds") or the shares of common stock of the Company in the United States or in any jurisdiction in which such offer or solicitation is unlawful. In particular, the Bonds and the shares of common stock of the Company issuable upon exercise of the stock acquisition rights (together, the "Securities") have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state or other jurisdictions of the United States, and any such Securities may not be offered or sold within the United States, absent registration or an exemption from registration under the Securities Act, and in compliance with any applicable state or local securities laws; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company. No public offering of the Securities will be made in the United States.